UroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024
UroGen Pharma Ltd. (URGN) will report fourth quarter and full-year 2023 financial results on March 14, 2024. The company focuses on developing solutions for urothelial and specialty cancers. Investors can join the live webcast and conference call at 10:00 AM ET on the same day.
03/04/2024 - 08:00 AM
Conference Call and Webcast Scheduled for Thursday, March 14, 2024, at 10:00 AM ET
PRINCETON, N.J. --(BUSINESS WIRE)--
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report fourth quarter and full-year 2023 financial results on Thursday, March 14, 2024, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time.
A live public webcast of the earnings conference call can be accessed on UroGen’s Investor Relations website . Following the live webcast, a replay will be available on the site for approximately 30 days.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Jelmyto® (mitomycin) for pyelocaliceal solution and investigational treatment UGN-102 (mitomycin) for intravesical solution are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel . Visit www.urogen.com to learn more or follow us on Twitter, @UroGenPharma.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240304990376/en/
INVESTORS:
vincent.perrone@urogen.com
MEDIA:
cindy.romano@urogen.com
Source: UroGen Pharma Ltd.
When will UroGen Pharma Ltd. report its fourth quarter and full-year 2023 financial results?
UroGen Pharma Ltd. (URGN) will report its fourth quarter and full-year 2023 financial results on Thursday, March 14, 2024.
What is UroGen Pharma Ltd.'s focus area?
UroGen Pharma Ltd. (URGN) focuses on developing and commercializing innovative solutions for urothelial and specialty cancers.
When is the live audio webcast and conference call scheduled?
The live audio webcast and conference call is scheduled for 10:00 AM Eastern Time on Thursday, March 14, 2024.
Where can investors access the live public webcast of the earnings conference call?
Investors can access the live public webcast of the earnings conference call on UroGen's Investor Relations website.
How long will the replay of the webcast be available?
A replay of the webcast will be available on the site for approximately 30 days after the live webcast.
URGN Rankings
#2431 Ranked by Stock Gains
URGN Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
Israel
City
9 Hataasiya St
About URGN
urogen pharma ltd. (nasdaq:urgn) is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. the company has developed rtgel™, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. urogen pharma's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. urogen pharma's lead product candidates, mitogel™ (mitomycin urothelial gel) and vesigel™ (mitomycin intravesical gel), are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma and bladder cancer, respectively. urogen pharma is headquartered in ra’anana, israel with u.s. headquarters in new york.
